News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmuneRegen BioSciences, Inc. (IRBO) Announces Material Transfer Agreement with HemoGenix Inc.


1/28/2008 9:25:53 AM

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), announces a Materials Transfer Agreement (MTA) with HemoGenix®, a Contract Research Service Laboratory that provides a 21st-century approach to developing stem cell assays for the biotechnology and pharmaceutical industry. Their high-throughput, cost-effective technology imparts standardization of stem cell assays, making HemoGenix a valuable collaborator. As part of the agreement, ImmuneRegen will ship its therapeutic candidate Homspera® for testing using a number of proprietary tools developed and validated by HemoGenix.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES